Repare Therapeutics Inc. (RPTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 7171 FREDERICK BANTING
SAINT-LAURENT, QC H4S 1Z9
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments280,692,000314,124,000343,941,000370,353,000282,089,000311,664,000
Cash and cash equivalents115,544,000121,461,000159,521,000155,191,000275,834,000305,136,000
Short-term investments165,148,000192,663,000184,420,000215,162,0006,255,0006,528,000
Receivables5,281,0003,996,0001,525,0009,626,000  
Prepaid expense4,201,0004,389,0005,715,0005,635,0003,242,0003,915,000
Other undisclosed current assets 1,751,0003,017,0002,798,0004,983,0004,407,0003,649,000
Total current assets:291,925,000325,526,000353,979,000390,597,000289,738,000319,228,000
Noncurrent Assets
Operating lease, right-of-use asset4,434,0004,976,0005,371,0005,904,0006,456,0007,003,000
Nontrade receivables      
Property, plant and equipment4,821,0005,396,0004,228,0004,683,0005,124,0005,397,000
Deferred income tax assets    7,477,0006,229,0004,935,000
Other noncurrent assets408,000408,000497,000497,000497,000586,000
Total noncurrent assets:9,663,00010,780,00010,096,00018,561,00018,306,00017,921,000
TOTAL ASSETS:301,588,000336,306,000364,075,000409,158,000308,044,000337,149,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,679,00011,349,0007,997,00018,919,00013,223,0006,720,000
Taxes payable1,870,000
Employee-related liabilities4,479,0003,694,0002,068,000
Accounts payable4,893,0003,620,000461,0009,345,0004,991,0001,546,000
Accrued liabilities4,786,0007,729,0007,536,0005,095,0004,538,0001,236,000
Deferred revenue24,412,00052,760,00053,102,00034,784,00011,855,00011,874,000
Other liabilities250,000159,000271,000255,000593,000328,000
Other undisclosed current liabilities18,912,00016,667,00017,249,0007,913,00013,769,00015,161,000
Total current liabilities:53,253,00080,935,00078,619,00061,871,00039,440,00034,083,000
Noncurrent Liabilities
Long-term debt and lease obligation:    3,767,0004,495,0005,154,000
Liabilities, other than long-term debt2,921,0004,127,0005,939,00037,744,00038,592,00039,252,000
Deferred revenue695,0001,347,0002,682,00037,744,00038,592,00039,252,000
Operating lease, liability2,226,0002,780,0003,257,0003,767,0004,495,0005,154,000
Total noncurrent liabilities:2,921,0004,127,0005,939,00041,511,00043,087,00044,406,000
Total liabilities:56,174,00085,062,00084,558,000103,382,00082,527,00078,489,000
Equity
Equity, attributable to parent245,414,000251,244,000279,517,000305,776,000225,517,000258,660,000
Common stock482,739,000482,677,000482,032,000481,782,000481,380,000481,048,000
Additional paid in capital49,299,00043,056,00037,226,00032,173,00027,253,00022,635,000
Accumulated other comprehensive loss(424,000)(235,000)(428,000)(524,000)  
Accumulated deficit(286,200,000)(274,254,000)(239,313,000)(207,655,000)(283,116,000)(245,023,000)
Total equity:245,414,000251,244,000279,517,000305,776,000225,517,000258,660,000
TOTAL LIABILITIES AND EQUITY:301,588,000336,306,000364,075,000409,158,000308,044,000337,149,000

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Gross profit:      (544,000)
Operating expenses(42,507,000)(40,359,000)(37,830,000)(39,146,000)(39,413,000)(35,237,000)
Other undisclosed operating income30,249,0005,678,00018,198,000112,545,000679,000952,000
Operating income (loss):(12,258,000)(34,681,000)(19,632,000)73,399,000(38,734,000)(34,829,000)
Nonoperating income3,422,0003,356,0003,002,0002,116,000674,000104,000
Investment income, nonoperating3,489,0003,427,0002,931,0002,027,000544,000129,000
Gain (loss), foreign currency transaction, before tax(41,000)(56,000)58,000126,000141,000(17,000)
Income (loss) from continuing operations before income taxes:(8,836,000)(31,325,000)(16,630,000)75,515,000(38,060,000)(34,725,000)
Income tax expense (benefit)(3,110,000)(3,616,000)(15,028,000)(54,000)(33,000)(32,000)
Income (loss) from continuing operations:(11,946,000)(34,941,000)(31,658,000)75,461,000(38,093,000)(34,757,000)
Income (loss) before gain (loss) on sale of properties:75,461,000(38,093,000)(34,757,000)
Net income (loss) available to common stockholders, diluted:(11,946,000)(34,941,000)(31,658,000)75,461,000(38,093,000)(34,757,000)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(11,946,000)(34,941,000)(31,658,000)75,461,000(38,093,000)(34,757,000)
Other comprehensive income (loss)(189,000)193,000 (524,000)  
Other undisclosed comprehensive loss   (428,000)   
Comprehensive income (loss):(12,135,000)(34,748,000)(32,086,000)74,937,000(38,093,000)(34,757,000)
Other undisclosed comprehensive income, net of tax, attributable to parent   524,000   
Comprehensive income (loss), net of tax, attributable to parent:(12,135,000)(34,748,000)(31,562,000)74,937,000(38,093,000)(34,757,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: